Commonwealth Serum Laboratories (CSL), an Australian biotechnology company and the world’s second-biggest flu vaccine manufacturer, has agreed to pay $312 million ($US200 million) to use groundbreaking mRNA vaccine technology from a U.S. company.
The vaccine manufacturer announced on Nov. 2 that it had licenced the new technology with Arcturus Therapeutics, an American mRNA medicines biotechnology company.
